EXHIBIT 99
Published on July 16, 2008
EXHIBIT
99
FOR
IMMEDIATE RELEASE
| CONTACT: | |
| Beth Bittle, Communications Manager | |
| 240-268-5300, ext. 307 |
REXAHN
PHARMACEUTICALS APPOINTS CHIEF BUSINESS OFFICER
Rockville, Maryland, July 14,
2008 – Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in
innovative therapeutics for life-threatening and life-debilitating diseases,
today announced the appointment of Rick Soni as Chief Business
Officer.
Rick Soni
joins Rexahn from Otsuka America Pharmaceuticals, Inc. At Rexahn, he will be
responsible for global business and corporate development. Mr. Soni will serve
on the Company’s executive management team and will report directly to Chang
Ahn, Ph.D., Chief Executive Officer. “We are pleased to welcome Rick to the
senior management team of Rexahn,” said Dr. Ahn. “Rick is a proven business
development executive as a leader of highly productive international teams and
will be a key contributor to Rexahn’s future success by developing new partner
relationships and securing new product opportunities.”
Mr. Soni
brings over 20 years of marketing and business development experience in
pharmaceutical industry to his new role at Rexahn. Immediately prior to joining
Rexahn, he served as Director of Commercialization and Business Development at
Otsuka America Pharmaceuticals, Inc., with responsibility for corporate strategy
and execution of licensing and acquisition of therapeutics, diagnostics and
medical devices. Previously, Rick has held variety of management positions at
Novartis and Schering-Plough. Rick has a BS in Engineering and Chemistry from
University of Wisconsin and an MBA from Fairleigh Dickinson
University.
About Rexahn Pharmaceuticals,
Inc.
Rexahn
Pharmaceuticals is a biopharmaceutical company leveraging its proprietary
technology platform to discover, develop and commercialize innovative treatments
for cancer, central nervous system disorders, sexual dysfunction and other unmet
medical needs. Rexahn’s compounds are designed to uniquely treat various disease
states while significantly minimizing side effects in order to allow patients to
regain their quality of life. For Additional information about Rexahn visit
www.rexahn.com
Safe
Harbor
This
press release contains statements (including projections and business trends)
that are forward-looking statements. Rexahn's actual results may differ
materially from the anticipated results and expectations expressed in these
forward-looking statements as a result of certain risks and uncertainties,
including, Rexahn's lack of profitability, its auditor's going concern
qualification and the need for additional capital to operate its business to
develop its product candidates; the risk that Rexahn's development efforts
relating to its product candidates may not be successful; the possibility of
being unable to obtain regulatory approval of Rexahn's product candidates; the
risk that the results of clinical trials may not be completed on time or support
Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates;
Rexahn's reliance on third party researchers and manufacturers to develop its
product candidates; Rexahn's ability to develop and obtain protection of its
intellectual property; and other risk factors set forth from time to time in our
filings with the Securities and Exchange Commission. These forward-looking
statements are made as of the date hereof; Rexahn assumes no obligation to
update these forward-looking statements.